米鲁姆制药
MIRM
80.14
-2.25
-2.73%
米鲁姆制药
US · MIRM
#2051 按市值排名
上市于 2019
80.14
-2.25
-2.73%
实时 - 追踪5344个代码 - 心跳于562秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了0.4个百分点。
机构持股
- 机构持股比例
- 111.86% -0.43pp
- 机构数量
- 403
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund77.60%
VC/PE Fund16.87%
Hedge Fund11.91%
Public Company2.96%
Individual/Insider1.29%
Private Company1.24%
Government Pension Fund0.64%
Sovereign Wealth Fund0.30%
Insurance Company0.27%
主要股东 截至 2026-06-30
Frazier Life Sciences Management, LP
11.83% · 7.68M 股
Janus Henderson Group plc
9.10% · 5.91M 股
BlackRock
6.76% · 4.39M 股
FMR
5.65% · 3.67M 股
T. Rowe Price Group, Inc.
4.09% · 2.66M 股
Vanguard Capital Management, LLC
4.01% · 2.60M 股
Vanguard Portfolio Management, LLC
3.66% · 2.38M 股
State Street Global Advisors
3.34% · 2.17M 股
William Blair Investment Management, LLC
2.16% · 1.40M 股
Geode Capital Management, LLC
2.15% · 1.39M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 22次买入 · 27次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 11.83% |
| Christopher Peetz | Chief Executive Officer | 0.59% |
| Michael Grey | Chairperson | 0.43% |
| Peter Radovich | Chief Operating Officer | 0.09% |
| Eric Bjerkholt | Chief Financial Officer | 0.07% |
| Joanne M. Quan | Chief Medical Officer | 0.03% |
| Laura Brege | Independent Director | 0.02% |
| Laurent Fischer | Independent Director | 0.02% |
| Timothy Walbert | Independent Director | 0.01% |
| Lon Cardon | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-20 | Rob Myers | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-13 | Eric Bjerkholt | Chief Financial Officer | Derivative Exercise and Sale | -9,943 | $98.37 |
| 2026-09-13 | Eric Bjerkholt | Chief Financial Officer | Intent to Sell (Form 144) | -9,943 | $98.37 |
| 2026-09-10 | Eric Bjerkholt | Chief Financial Officer | Derivative Exercise and Retained | +8,390 | -- |
| 2026-09-01 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -658 | $100.00 |
| 2026-08-31 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -30,000 | $2.94–98.91 |
| 2026-08-17 | Jolanda Howe | Senior VP & Global Controller | Derivative Exercise and Sale | -40,000 | $6.27–100.00 |
| 2026-08-10 | Eric Bjerkholt | Chief Financial Officer | Automatic Disposition | -6,001 | $99.90 |
| 2026-08-09 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -20,000 | $2.94–100.14 |
| 2026-08-02 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -1,840 | $105.29 |
| 2026-07-05 | Eric Bjerkholt | Chief Financial Officer | Automatic Disposition | -5,000 | $121.67–124.94 |
| 2026-07-05 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -20,000 | $2.94–124.79 |
| 2026-06-30 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -2,721 | $120.00 |
| 2026-06-16 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -2,594 | $101.95 |
| 2026-06-14 | Patrick Heron | Independent Director | Other Derivative Acquisition | +1,980 | -- |
| 2026-06-14 | Patrick Heron | Independent Director | Other Derivative Acquisition | +3,772 | $101.00 |
| 2026-06-14 | Laura Brege | Independent Director | Other Derivative Acquisition | +1,980 | -- |
| 2026-06-14 | Laura Brege | Independent Director | Other Derivative Acquisition | +3,772 | $101.00 |
| 2026-06-14 | Michael Grey | Chairperson | Other Derivative Acquisition | +1,980 | -- |
| 2026-06-14 | Michael Grey | Chairperson | Other Derivative Acquisition | +3,772 | $101.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
米鲁姆制药 讨论区 0 条评论